MX2017004943A - Tratamiento de la enfermedad del hígado graso usando antagonistas de receptores de glucocorticoides y de minerarlocorticoides. - Google Patents

Tratamiento de la enfermedad del hígado graso usando antagonistas de receptores de glucocorticoides y de minerarlocorticoides.

Info

Publication number
MX2017004943A
MX2017004943A MX2017004943A MX2017004943A MX2017004943A MX 2017004943 A MX2017004943 A MX 2017004943A MX 2017004943 A MX2017004943 A MX 2017004943A MX 2017004943 A MX2017004943 A MX 2017004943A MX 2017004943 A MX2017004943 A MX 2017004943A
Authority
MX
Mexico
Prior art keywords
liver disease
fatty liver
glucocorticoid
receptor antagonists
disease treatment
Prior art date
Application number
MX2017004943A
Other languages
English (en)
Spanish (es)
Inventor
K Belanoff Joseph
Hazel Hunt
C Meijer Onno
VAN DEN HEUVEL Jose
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2017004943A publication Critical patent/MX2017004943A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017004943A 2014-10-15 2015-10-14 Tratamiento de la enfermedad del hígado graso usando antagonistas de receptores de glucocorticoides y de minerarlocorticoides. MX2017004943A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
MX2017004943A true MX2017004943A (es) 2017-07-19

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004943A MX2017004943A (es) 2014-10-15 2015-10-14 Tratamiento de la enfermedad del hígado graso usando antagonistas de receptores de glucocorticoides y de minerarlocorticoides.

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11202011948SA (en) * 2018-06-04 2020-12-30 Corcept Therapeutics Inc Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
US11548856B2 (en) * 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US12144812B2 (en) * 2020-05-06 2024-11-19 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
WO2022140293A1 (en) * 2020-12-21 2022-06-30 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022235647A1 (en) * 2021-05-05 2022-11-10 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PE20090695A1 (es) 2007-04-13 2009-06-27 Schering Corp Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
US12226417B2 (en) 2025-02-18
AU2015333645B2 (en) 2020-01-30
PL3206692T3 (pl) 2024-07-22
AU2015333645A1 (en) 2017-05-04
BR112017007860A2 (pt) 2018-01-16
US20210085682A1 (en) 2021-03-25
EP3206692A4 (en) 2018-05-30
US20160106749A1 (en) 2016-04-21
FI3206692T3 (fi) 2024-05-06
NZ731060A (en) 2023-07-28
CA2964625C (en) 2023-03-07
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
JP2017531013A (ja) 2017-10-19
CN111557942A (zh) 2020-08-21
RU2017114596A (ru) 2018-11-15
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
SG11201703024VA (en) 2017-05-30
EP3206692A1 (en) 2017-08-23
EP4353310A2 (en) 2024-04-17
EP3206692B1 (en) 2024-04-03
JP6761410B2 (ja) 2020-09-23
DK3206692T3 (da) 2024-04-29
US11590135B2 (en) 2023-02-28
PH12017500710B1 (en) 2024-01-17
CN107106562B (zh) 2020-08-18
PH12017500710A1 (en) 2017-10-09
KR20170066646A (ko) 2017-06-14
ZA201702813B (en) 2019-05-29
RU2017114596A3 (OSRAM) 2019-05-08
UA123537C2 (uk) 2021-04-21
US20230218621A1 (en) 2023-07-13
CA2964625A1 (en) 2016-04-21
RU2718921C2 (ru) 2020-04-15
IL251729B (en) 2020-03-31
US10238659B2 (en) 2019-03-26
US20190151318A1 (en) 2019-05-23
ES2978871T3 (es) 2024-09-23
IL251729A0 (en) 2017-06-29
EP4353310A3 (en) 2024-06-19
WO2016061195A1 (en) 2016-04-21
BR112017007860B1 (pt) 2023-03-07
KR102435956B1 (ko) 2022-08-23

Similar Documents

Publication Publication Date Title
PH12017500710A1 (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
ZA202308495B (en) Pharmaceutical compositions of therapeutically active compounds
MX2020014300A (es) Compuestos heterociclicos utiles en el tratamiento de enfermedades.
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX381417B (es) Inhibidores de glucosidasa.
EA201692316A1 (ru) Производные холана для применения при лечении и/или профилактике fxr и tgr5/gpbar1-опосредованных заболеваний
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
NZ720478A (en) Autotaxin inhibitor compounds
PH12016501788B1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201691808A8 (ru) Кортикостероидные композиции для местного применения
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
WO2018067520A3 (en) Therapeutic agents and methods:
MX2016014559A (es) Compuestos para el tratamiento de cancer.
MX382175B (es) Composiciones de profármaco de monometilfumarato
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX2015012318A (es) Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf.
EA201692020A1 (ru) Пролекарственные средства янтарной кислоты для применения в лечении лактоацидоза или индуцируемого лекарственными средствами побочного действия вследствие связанных с комплексом i нарушений окислительного фосфорилирования в митохондриях
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
ZA201606135B (en) Pharmaceutical compositions of therapeutically active compounds
AU2015902659A0 (en) Therapeutic compounds and compositions for treating social disorders and substance use disorders

Legal Events

Date Code Title Description
FG Grant or registration